secwatch.observer — SEC 8-K summary
======================================

Issuer:     Merck & Co., Inc. (MRK)
CIK:        0000310158
Form:       8-K
Filed at:   2024-02-01T23:59:59+00:00
Accession:  0001104659-24-009109
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Merck reports Q4 GAAP loss of $0.48/share; plans $4B restructuring; FY2024 EPS guidance $8.44-8.59
--------------------------------------------------------------------------------

- Q4 2023 GAAP net loss $1.2B ($0.48 loss per share); non-GAAP EPS $0.03, includes $1.69/share Daiichi Sankyo charge.
- Full-year 2023 sales $60.1B (+1% YoY); KEYTRUDA $25B (+19%), GARDASIL $8.9B (+29%), LAGEVRIO down 75% to $1.4B.
- FY 2024 outlook: sales $62.7-64.2B; non-GAAP EPS $8.44-8.59.
- Approved 2024 Restructuring Program with cumulative pretax costs ~$4B; ~60% non-cash; substantially complete by end of 2031.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/310158/000110465924009109/0001104659-24-009109-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/310158/000110465924009109/tm244517d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-009109

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer